From: Microsatellite instability: a review of what the oncologist should know
Drug | Target | Indications | Remarks | Refs. |
---|---|---|---|---|
Fluorouracil | Nucleic acid | Stage III to IV CRC | Chemotherapy | Kwon et al. [81] |
Nivolumab | PD-L1 | Patients with advanced metastatic CRC over the age of 12Â years with MSI-H/dMMR; BRAF mutation caused by dMMR/MSI-H metastatic CRC | Based on the chemotherapy drug treatment | Overman et al. [87] |
Ipilimumab | CTLA4 | Combined treatment with Nivolumab for metastatic CRC aggravated by MSI-H/dMMR after oxaliplatin, irinotecan and fluorouracil | Low dose ipilimumab combined with nivolumab can reduce side effects in patients | Overman et al. [89] |
Pembrolizumab | PD-L1 | Advanced anti-PD-L1 positive CRC patients | Based on the chemotherapy drug treatment | O’Neil et al. [91] |
Bevacizumab | VEGF | Patients with MSI-H tumor | Based on the chemotherapy drug treatment | Innocenti et al. [92] |